Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses in Subjects Treated Early after Infection

ABSTRACT Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have preserved HIV-1-specific CD4+ T-cell function. We studied the effect of highly active antiretroviral therapy (HAART) on the frequency of HIV-1-specific CD8+ T cells in patients treated during early (n = 31) or chronic (n = 23) infection. The degree of viral suppression and time of initiation of treatment influenced the magnitude of the CD8+ T-cell response. HIV-1-specific CD8+ T cells can increase in number after HAART in subjects treated early after infection who have episodes of transient viremia.

[1]  Stefan Kostense,et al.  High viral burden in the presence of major HIV‐specific CD8+ T cell expansions: evidence for impaired CTL effector function , 2001, European journal of immunology.

[2]  S. Rowland-Jones,et al.  Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.

[3]  J. Kahn,et al.  Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Rosenberg,et al.  Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection , 2001, The Journal of experimental medicine.

[5]  T. Perneger,et al.  Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection , 2000, AIDS.

[6]  E. Rosenberg,et al.  Functionally Inert HIV-Specific Cytotoxic T Lymphocytes Do Not Play a Major Role in Chronically Infected Adults and Children , 2000, The Journal of experimental medicine.

[7]  B. Walker,et al.  The Role of CD4+ T Cell Help and CD40 Ligand in the In Vitro Expansion of HIV-1-Specific Memory Cytotoxic CD8+ T Cell Responses , 2000, The Journal of Immunology.

[8]  M. Mulligan,et al.  A Significant Number of Human Immunodeficiency Virus Epitope-Specific Cytotoxic T Lymphocytes Detected by Tetramer Binding Do Not Produce Gamma Interferon , 2000, Journal of Virology.

[9]  J. Lieberman,et al.  Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. , 2000, Blood.

[10]  E. Rosenberg,et al.  Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Ho,et al.  An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes , 2000, Molecular medicine.

[12]  Alessandro Sette,et al.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.

[13]  J. Lieberman,et al.  Human Immunodeficiency Virus-Specific Circulating CD8 T Lymphocytes Have Down-Modulated CD3ζ and CD28, Key Signaling Molecules for T-Cell Activation , 2000, Journal of Virology.

[14]  V. Calvez,et al.  Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1 , 2000, The Journal of Immunology.

[15]  Douglas D. Richman,et al.  HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function , 2000, The Journal of experimental medicine.

[16]  D. Nixon,et al.  The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children. , 2000, The Journal of infectious diseases.

[17]  M. Saag,et al.  Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR. , 2000, Journal of virological methods.

[18]  J. Margolick,et al.  Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ T-Lymphocyte Reactivity during Combination Antiretroviral Therapy in HIV-1-Infected Patients with Advanced Immunodeficiency , 2000, Journal of Virology.

[19]  D. Nixon,et al.  Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.

[20]  P. Easterbrook,et al.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Yoder,et al.  Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. , 1999, AIDS.

[22]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[23]  Alan S. Perelson,et al.  Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.

[24]  J. Guillet,et al.  Broad, Intense Anti-Human Immunodeficiency Virus (HIV) Ex Vivo CD8+ Responses in HIV Type 1-Infected Patients: Comparison with Anti-Epstein-Barr Virus Responses and Changes during Antiretroviral Therapy , 1999, Journal of Virology.

[25]  D. Nixon,et al.  Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. , 1999, The Journal of infectious diseases.

[26]  B. Walker,et al.  Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy , 1999, Journal of Virology.

[27]  N. Foudraine,et al.  Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. , 1999, The Journal of infectious diseases.

[28]  D. Cooper,et al.  CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia. , 1999, The Journal of infectious diseases.

[29]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[30]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[31]  Martin A. Nowak,et al.  Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA , 1999, The Journal of experimental medicine.

[32]  R. Steinman,et al.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. , 1999, AIDS.

[33]  T. Merigan,et al.  Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). , 1999, Journal of immunology.

[34]  M. Nowak,et al.  Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy , 1999, Journal of Virology.

[35]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[36]  B. Hoen,et al.  Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. , 1998, The Journal of infectious diseases.

[37]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[38]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[39]  J. Margolick,et al.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[40]  M. McElrath,et al.  Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.

[41]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.

[42]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.

[43]  A. Fauci,et al.  Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.